| ID | 1150 |
| Name of the vaccine | MenHibrix |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 6 weeks to 18 months |
| Description of the vaccine | Meningococcal groups C and Y and Haemophilus b tetanus toxoid conjugate vaccine. |
| Name of the manufacturer | GlaxoSmithKline Biologicals |
| Name of the manufacturing country | Belgium |
| Year of manufacture | 2012 |
| Clinical Phase status | Approved |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | Conducted with unconjugated Haemophilus b polysaccharide vaccine. |
| Vaccine formulation | Single-dose vial of lyophilized vaccine reconstituted with saline diluent. |
| Dosage | Four doses (0.5 mL each) at 2, 4, 6, and 12 through 15 months. |
| Mechanism of action | Anti-PRP concentration of 0.15 mcg/mL : minimal protection
Anti-PRP concentration of greater than or equal to 1.0 mcg/mL : Protection for 1 year |
| Route of administration | Intramuscular |
| Indications | Prevents invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. |
| Export | Distributed by - GlaxoSmithKline |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | For Meningococcal (groups C and Y). |
| Side effects of vaccine | Injection site pain, redness, and swelling, irritability, drowsiness, loss of appetite and fever. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/83688/download |
| Other name | NA |
| Additional Links | NA
|